BC Innovations | May 17, 2018

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
BC Innovations | Apr 17, 2018
Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing...
BC Innovations | Aug 16, 2017
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Self-assembling multicellular BBB spheroids could help screen compounds for BBB permeability. The spheroids self-assembled from co-cultures of primary human astrocytes, brain vascular pericytes and either brain microvascular endothelial cells or a human...
BC Innovations | Jul 26, 2017
Emerging Company Profile

Breaching the gates

Junction Therapeutics Ltd. ’s siRNA-based technology creates transient openings in the blood-brain barrier by targeting tight junction proteins, allowing molecules to move in and out of the brain by diffusion. The approach enhances entry of...
BC Innovations | Dec 3, 2015
Translation in Brief

IL-17A's autoimmune dichotomy

A pair of studies has resolved the conundrum of why blocking IL-17A helps in psoriasis but exacerbates Crohn's disease, and highlights the dangers of assuming that hitting a target in autoimmunity will have the same...
BC Innovations | Oct 8, 2015
Translation in Brief

Holey BBB

A study from Trinity College Dublin has shown that reducing the levels of two tight junction proteins can loosen the blood-brain barrier and let soluble β-amyloid monomers slip out of the brain through the spaces...
BC Innovations | Oct 1, 2015
Distillery Therapeutics

Therapeutics: Claudin 5 (CLDN5); occludin (OCLN); β amyloid (Aβ)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest inhibiting CLDN5 and OCLN could help treat AD. In endothelial cell cultures, knockdown of both CLDN5 and OCLN increased paracellular diffusion of Aβ monomers...
BC Innovations | Sep 5, 2013
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Transgenic, humanized mouse model of HCV infection Partially immunocompromised, humanized mice could be used as a model of HCV infection to help evaluate antiviral drug...
BC Innovations | Jun 16, 2011
Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Immunocompetent, humanized mouse model for HCV infection An immunocompetent, humanized mouse model of HCV could help evaluate potential HCV entry inhibitors...
BC Innovations | Jun 16, 2011
Cover Story

HCV's mighty mouse

The most widely used animal model of HCV infection requires transplanting human hepatocytes into immunodeficient mice. These mice are useful for testing antivirals, but the absence of an immune system makes the animals unsuitable for...
Items per page:
1 - 10 of 13